WO2004028434A2 - Nocturnal muscle enhancing composition and method - Google Patents
Nocturnal muscle enhancing composition and method Download PDFInfo
- Publication number
- WO2004028434A2 WO2004028434A2 PCT/US2003/031072 US0331072W WO2004028434A2 WO 2004028434 A2 WO2004028434 A2 WO 2004028434A2 US 0331072 W US0331072 W US 0331072W WO 2004028434 A2 WO2004028434 A2 WO 2004028434A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- composition
- mixture
- proteins
- amino acids
- weight
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 140
- 238000000034 method Methods 0.000 title claims abstract description 24
- 230000000422 nocturnal effect Effects 0.000 title claims abstract description 16
- 230000002708 enhancing effect Effects 0.000 title claims description 4
- 210000003205 muscle Anatomy 0.000 title description 19
- 230000007958 sleep Effects 0.000 claims abstract description 35
- 150000001413 amino acids Chemical class 0.000 claims abstract description 30
- 235000021245 dietary protein Nutrition 0.000 claims abstract description 18
- 235000018102 proteins Nutrition 0.000 claims description 37
- 102000004169 proteins and genes Human genes 0.000 claims description 37
- 108090000623 proteins and genes Proteins 0.000 claims description 37
- 235000001014 amino acid Nutrition 0.000 claims description 29
- 235000016709 nutrition Nutrition 0.000 claims description 19
- 230000037257 muscle growth Effects 0.000 claims description 11
- 108010046377 Whey Proteins Proteins 0.000 claims description 10
- 239000012730 sustained-release form Substances 0.000 claims description 10
- 108010011756 Milk Proteins Proteins 0.000 claims description 9
- 102000014171 Milk Proteins Human genes 0.000 claims description 9
- 235000021239 milk protein Nutrition 0.000 claims description 9
- 235000021119 whey protein Nutrition 0.000 claims description 9
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 8
- 239000000843 powder Substances 0.000 claims description 8
- 238000013268 sustained release Methods 0.000 claims description 8
- 241000209140 Triticum Species 0.000 claims description 7
- 235000021307 Triticum Nutrition 0.000 claims description 7
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- 230000008569 process Effects 0.000 claims description 7
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 6
- 239000002552 dosage form Substances 0.000 claims description 6
- 239000003797 essential amino acid Substances 0.000 claims description 6
- 235000020776 essential amino acid Nutrition 0.000 claims description 6
- 229940067606 lecithin Drugs 0.000 claims description 6
- 235000010445 lecithin Nutrition 0.000 claims description 6
- 239000000787 lecithin Substances 0.000 claims description 6
- 239000011785 micronutrient Substances 0.000 claims description 6
- 235000013369 micronutrients Nutrition 0.000 claims description 6
- 230000001939 inductive effect Effects 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 5
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 4
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 4
- 108010073771 Soybean Proteins Proteins 0.000 claims description 4
- 229940124325 anabolic agent Drugs 0.000 claims description 4
- 239000003263 anabolic agent Substances 0.000 claims description 4
- 102000007544 Whey Proteins Human genes 0.000 claims description 3
- 230000037406 food intake Effects 0.000 claims description 3
- 239000007787 solid Substances 0.000 claims description 3
- 229940001941 soy protein Drugs 0.000 claims description 3
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 2
- 239000004475 Arginine Substances 0.000 claims description 2
- 239000004471 Glycine Substances 0.000 claims description 2
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 claims description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 2
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 claims description 2
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 claims description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 2
- 235000009582 asparagine Nutrition 0.000 claims description 2
- 235000003704 aspartic acid Nutrition 0.000 claims description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 2
- 229960003104 ornithine Drugs 0.000 claims description 2
- 150000001508 asparagines Chemical class 0.000 claims 1
- 239000000122 growth hormone Substances 0.000 abstract description 18
- 102000018997 Growth Hormone Human genes 0.000 abstract description 17
- 108010051696 Growth Hormone Proteins 0.000 abstract description 17
- 235000015872 dietary supplement Nutrition 0.000 abstract description 9
- 230000002459 sustained effect Effects 0.000 abstract description 8
- 229940024606 amino acid Drugs 0.000 description 21
- 239000012141 concentrate Substances 0.000 description 15
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 13
- 230000001195 anabolic effect Effects 0.000 description 8
- 235000015097 nutrients Nutrition 0.000 description 8
- 235000010469 Glycine max Nutrition 0.000 description 7
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 7
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 7
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 7
- 229960000310 isoleucine Drugs 0.000 description 7
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 7
- 229960003136 leucine Drugs 0.000 description 7
- 239000004474 valine Substances 0.000 description 7
- 235000019454 L-leucine Nutrition 0.000 description 6
- 239000004395 L-leucine Substances 0.000 description 6
- 230000015556 catabolic process Effects 0.000 description 6
- 235000005911 diet Nutrition 0.000 description 6
- 230000000378 dietary effect Effects 0.000 description 6
- 150000001720 carbohydrates Chemical class 0.000 description 5
- 235000014633 carbohydrates Nutrition 0.000 description 5
- 229930091371 Fructose Natural products 0.000 description 4
- 239000005715 Fructose Substances 0.000 description 4
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 4
- 229910052802 copper Inorganic materials 0.000 description 4
- 239000010949 copper Substances 0.000 description 4
- 229940108928 copper Drugs 0.000 description 4
- 235000013367 dietary fats Nutrition 0.000 description 4
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 description 4
- 229940107187 fructooligosaccharide Drugs 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000003094 microcapsule Substances 0.000 description 4
- 239000011669 selenium Substances 0.000 description 4
- 229910052711 selenium Inorganic materials 0.000 description 4
- 229940088594 vitamin Drugs 0.000 description 4
- 239000011782 vitamin Substances 0.000 description 4
- 235000013343 vitamin Nutrition 0.000 description 4
- 229930003231 vitamin Natural products 0.000 description 4
- 239000011719 vitamin A Substances 0.000 description 4
- 229940046009 vitamin E Drugs 0.000 description 4
- 239000011709 vitamin E Substances 0.000 description 4
- 229940045997 vitamin a Drugs 0.000 description 4
- 102000015781 Dietary Proteins Human genes 0.000 description 3
- 108010010256 Dietary Proteins Proteins 0.000 description 3
- 206010062767 Hypophysitis Diseases 0.000 description 3
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 3
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 3
- RDHQFKQIGNGIED-MRVPVSSYSA-N O-acetyl-L-carnitine Chemical compound CC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C RDHQFKQIGNGIED-MRVPVSSYSA-N 0.000 description 3
- 244000299461 Theobroma cacao Species 0.000 description 3
- 235000009470 Theobroma cacao Nutrition 0.000 description 3
- 235000020221 chamomile extract Nutrition 0.000 description 3
- 229940119217 chamomile extract Drugs 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 235000020689 passion flower extract Nutrition 0.000 description 3
- 229940001884 passion flower extract Drugs 0.000 description 3
- 210000003635 pituitary gland Anatomy 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 235000005974 protein supplement Nutrition 0.000 description 3
- 229940116540 protein supplement Drugs 0.000 description 3
- -1 such as Substances 0.000 description 3
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 3
- 229940038779 valerian root extract Drugs 0.000 description 3
- 239000001192 valeriana officinalis l. rhizome/root Substances 0.000 description 3
- 239000008371 vanilla flavor Substances 0.000 description 3
- 150000003722 vitamin derivatives Chemical class 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000003160 anti-catabolic effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 229930003935 flavonoid Natural products 0.000 description 2
- 235000017173 flavonoids Nutrition 0.000 description 2
- 150000002215 flavonoids Chemical class 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 235000008216 herbs Nutrition 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- AGBQKNBQESQNJD-UHFFFAOYSA-N lipoic acid Chemical compound OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 description 2
- 229960001983 magnesium aspartate Drugs 0.000 description 2
- CRSJYWPXKKSOCQ-CBAPHJFVSA-L magnesium;(2s)-2-aminobutanedioate;hydron;tetrahydrate Chemical compound O.O.O.O.[Mg+2].[O-]C(=O)[C@@H](N)CC(O)=O.[O-]C(=O)[C@@H](N)CC(O)=O CRSJYWPXKKSOCQ-CBAPHJFVSA-L 0.000 description 2
- 229960003987 melatonin Drugs 0.000 description 2
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 230000021332 multicellular organism growth Effects 0.000 description 2
- 239000006186 oral dosage form Substances 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 238000001243 protein synthesis Methods 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 2
- 230000002618 waking effect Effects 0.000 description 2
- UOXSXMSTSYWNMH-UHFFFAOYSA-L zinc;2-aminoacetate Chemical compound [Zn+2].NCC([O-])=O.NCC([O-])=O UOXSXMSTSYWNMH-UHFFFAOYSA-L 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 description 1
- 102000002265 Human Growth Hormone Human genes 0.000 description 1
- 108010000521 Human Growth Hormone Proteins 0.000 description 1
- 239000000854 Human Growth Hormone Substances 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 102000008934 Muscle Proteins Human genes 0.000 description 1
- 108010074084 Muscle Proteins Proteins 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 239000005862 Whey Substances 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000000619 acesulfame-K Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 210000003022 colostrum Anatomy 0.000 description 1
- 235000021277 colostrum Nutrition 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 1
- 150000002515 isoflavone derivatives Chemical class 0.000 description 1
- 235000008696 isoflavones Nutrition 0.000 description 1
- 235000019136 lipoic acid Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229920000620 organic polymer Polymers 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 235000011649 selenium Nutrition 0.000 description 1
- 229940091258 selenium supplement Drugs 0.000 description 1
- 230000037322 slow-wave sleep Effects 0.000 description 1
- 235000021055 solid food Nutrition 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 229960002663 thioctic acid Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 229940005605 valeric acid Drugs 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/19—Dairy proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/185—Vegetable proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Definitions
- This invention relates to health supplements and, more particularly, to novel systems and methods for counteracting nocturnal post-absorptive muscle catabolism using slowly assimilated proteins, herbs, and minerals.
- NPMC BACKGROUND Nocturnal Post- Absorptive Muscle Catabolism
- NPMC is a naturally occurring phenomena in the human body. It occurs every night during the later hours of sleep, after the release of the body's growth hormone has abated, and drastically cuts the body's ability to synthesize new protein.
- Another key to achieving muscle growth and repair is having an adequate supply of available proteins when growth hormone is released by the body.
- stress factors greatly reduce the probability that the protein serving will contribute to protein synthesis and will also disrupt whatever constructive synthesis may be taking place at the moment of waking.
- the only viable solution to the problem is the invention envisioned herein, whereby proteins, fats and carbohydrates are provided in a manner that doesn't disrupt slow wave sleep, GH release or IG-F metabolism, but in fact helps to promote them.
- both a method and nutrient supplement composition for nocturnal administration are provided where the nutrient supplement composition includes a sustained timed release portion and a rapid release portion, both portions containing a mixture of edible food proteins and edible amino acid building blocks.
- a portion of these key components are microencapsulated for sustained timed release in the body during the growth hormone spikes that generally occur during nocturnal sleep.
- Administration of the sustained release portion acts to complement the components administered in rapid release form.
- the supplement of the present invention helps counteract "Nocturnal Post- Absorptive Muscle Catabolism" following the release of growth hormone and subsequently IGF-I in the body due to its sustained and rapid release portions.
- a composition and method of administering this composition to human subjects have been discovered which enhance or promote muscle growth in these human subjects.
- a method for building muscle mass (protein) occurs during deep nocturnal sleep when the body produces peak natural growth hormone release by the pituitary gland.
- muscle growth is provided during sleep by orally administering a nutritional supplement, containing a mixture of nutritional food proteins and edible amino acids, in two portions to the human subject just prior to retiring for nighttime sleep. The first portion of this mixture is administered in the form of microencapsulated particles containing this mixture for sustained time release during the sleep period and the second portion of this mixture is administered in the form for rapid release during the sleep period. h this manner, the release of these proteins and amino acids occurs to coincide with the bodies' peak release of natural growth hormones. In this way the NPMC can be reduced and new muscle proteins can be synthesized.
- muscle mass is built during the period of diurnal sleep cycle popularly known as deep sleep or Delta sleep, in association with the normal diurnal release by the pituitary gland of growth hormone.
- This nutritional supplement supplies the needed anabolic and anti-catabolic nutrients. This is the precise time of the 24 hour day in which high growth hormone levels are present, which utilize the nutrients for anabolic purposes. In this manner the need to catabolize proteins from other tissues to meet the anabolic demand put on the body by this growth hormone release is substantially reduced.
- a nutritional supplement composition and method for administering this composition to human subjects is provided to promote or enhance muscle growth by administering the composition so it is effective during the peak hours when proteins are catabolized to meet the bodies by high growth hormone release.
- This method comprises orally administering to a human subject, just prior to nighttime sleep, a mixture of nutritional food proteins and edible amino acids at a daily dosage of from about 10 to about 250 grams, preferably from about 10 to about 150 grams and most preferably from about 10 to about 50 grams.
- This mixture which contains nutritional food proteins and edible amino acids, can be administered in such a way that a portion of this mixture of nutritional food proteins and edible amino acids is microencapsulated for sustained release while the remaining or second portion of this mixture is in a form for simple, rapid release.
- These two portions can be orally administered in two separate doses or administered as a single oral dose. For example, these two portions can be taken together as a powder which is mixed with an edible liquid, such as, water, milk, juice, etc. and drunk before going to bed.
- compositions of this invention When the compositions of this invention are prepared as a powder in a single unit dosage form, they contain from about 10 to about 250 grams of the aforementioned mixture of nutritional food proteins and edible amino acids. Generally it is preferred that these unit dosage forms contain these mixtures in an amount of from about 10 to about 100 grams and most preferably from about 10 to about 50 grams.
- the powdered composition containing the mixture of nutritional food proteins and edible amino acids can be formulated as individual packets which contain from about 10 grams to about 50 grams of this mixture.
- the powdered mixture can be formulated into any conventional unit oral dosage form such as tablets, capsules, etc.
- these unit dosage forms containing both the time release and the rapid release form can be prepared in divided unit dosage forms so that when administered they can provide a total dose of from about 10 to about 50 grams of the mixture to the subject on a daily basis before the subject retires to sleep.
- these oral unit dosage forms a combination of the mixture of nutritional food proteins and edible amino acids in sustained and rapid release forms is administered which maintains the proper adjustments of this mixture in the body to enhance muscle growth during the period of deep sleep associated with peak natural growth hormone release.
- the composition should be administered during nighttime just before the human subject retires to bed for extended sleep. Generally, the mixture is administered within two hours prior to retiring for nocturnal sleep.
- best results are achieved when the mixture is administered within one-half hour prior to retiring for nocturnal sleep. It has been found that best results are achieved when the nightly administration occurs where the mixture contains from about 15% to about 70% by weight of the mixture (preferably from about 30% to 70% by weight) of nutritional food proteins and edible amino acids administered in the sustained release form, i.e., in the microencapsulated form and the remainder of the mixture being administered in the rapid release form. While good results are achieved through the use of these proportions of the sustained release to the rapid release forms of the mixture, it is preferred to utilize approximately equal proportions of this mixture for a given nightly administration, i.e., from about 45% to about 55% by weight being administered in the slow release form with the remainder of the mixture being administered in rapid release form.
- results of this invention are achieved by providing a mixture which contains from about 10% to about 95% by weight of the mixture of the edible nutritional food proteins and the remainder, i.e., from about 5% to about 90% by weight of mixture, of the edible dietary amino acids.
- best results are achieved by providing a mixture of from about 65% to about 95% of the protein with the remainder being the amino acids in an amount of from about 5% to about 35% by weight of the mixture.
- any of the conventional, nutritional proteins contained in food can be utilized to provide the proteins in this mixture.
- the preferred proteins are milk proteins, whey proteins, wheat proteins, soy proteins or mixtures thereof. These edible food proteins are the important proteins in muscles building.
- any of the conventional amino acids which are edible can be utilized in this invention.
- the preferred amino acids are the essential amino acids, i.e., leucine, lysine, threonine, isoleucine, valine, phenylalanine, methionine or tryptophan, as well as conventional edible dietary amino acids such as arginine, cysteine, cystine, glutamine, histadine, alanine, aspartic acid, asparagine, glycine, ornithine, serine, proline, tyrosine or mixtures thereof.
- any conventional means of microencapsulating this powdered mixture in a sustained release coating or semi- permeable membrane can be utilized.
- Microencapsulation is a known method whereby tiny particles of gas, liquid or solid, used as the active ingredient are enclosed in a secondary material in order to shield the active ingredient from its surrounding environment.
- the microcapsules of this invention may measure from about two microns to several millimeters for the purpose of releasing the mixture of nutritional food proteins and edible amino acids in a sustained manner.
- General procedures for forming microcapsules for sustained release dispensing of pharmaceuticals are disclosed in various U.S. Patents such as U.S. Patent 5,192,549 and are conventional in the art.
- these microcapsules utilize organic polymers which are tough yet flexible and form the outer skin for final microcapsule.
- these microcapsules are solid and can be mixed together with the second or rapid release portion to form a powder that can be utilized for administering the dietary proteins and amino acids mixture.
- these powders can be used as individual packets or further formulated into oral dosage forms if desired in accordance with usual tablet or capsule forming methods.
- compositions which enhance the activity of this composition can be added to the composition to augment or enhance the properties of the aforementioned mixture
- the composition contains in addition to the mixture, conventional anabolic materials suitable for human ingestion in an amount of from about 2% to about 10% by weight of the total composition.
- Any conventional anabolic material, suitable for human ingestion can be utilized such as vitamin B6, zinc chelazome and magnesium aspartate.
- these materials are present in the rapid release portion in an amount of from about 2% to about 10% by weight based upon the weight of the entire composition, i these compositions, these dietary edible anabolic agents enhance the activity of the protein and amino acid mixture in building body mass. They also increase protein synthesis, h addition to anabolic agents, it is preferred that the composition contain nutritional agents such as micronutrients. These micronutrients are present in the rapid release portion in an amount of from about 0.1% to 2% by weight of the total composition. Any conventional edible or dietary micronutrients such as vitamin A, vitamin E, selenium and copper can be present. The micronutrients also enhance the synthesis of proteins.
- the composition may contain nutritional agents such as dietary fats and carbohydrates that aid in the anabolic functions. These dietary fats and carbohydrates are usually present in the rapid release portion of this composition in an amount of from about 5% to 25% by weight, based upon the weight of the total composition.
- dietary fats and carbohydrates include dietary fats such as liquid soy and lecithin and carbohydrates such as fructose and fructo-oligosaccharide.
- any conventional dietary accepted sleeping agent such as passion flower extract, chamomile extract, valerian root extract or melatonin can be incorporated into the composition of this invention for the purpose of inducing sleep.
- these sleep-inducing agents are present in the rapid release portion in an amount of from 0.1% to 1% by weight based upon the total weight of the composition, hi addition, various ingredients such as L-taurine and acetyl-L-carnitine can be added for increasing a nighttime release of growth hormone and coinciding this release with the release of the dietary and nutrient proteins and amino acids.
- composition of this invention may contain conventional carriers, flavorents, coloring agents and/or other incipients to enhance the taste, feel and flavor of the composition. These include such ingredients as sucrose, sweeteners, or flavorings, etc. In addition, vitamins, herbs, minerals and nutrients can be added to this composition and provide desired properties which are conventional in the art.
- Vitamin Blend 0.090 0.19% -Vitamin A 1250 IU -Vitamin E 7.5 IU -Selenium 17.5 meg -Copper .5 mg
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Botany (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2003299088A AU2003299088A1 (en) | 2002-09-27 | 2003-09-26 | Nocturnal muscle enhancing composition and method |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/256,997 | 2002-09-27 | ||
US10/256,997 US7037522B2 (en) | 2002-09-27 | 2002-09-27 | Nocturnal muscle enhancing composition and method |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2004028434A2 true WO2004028434A2 (en) | 2004-04-08 |
WO2004028434A3 WO2004028434A3 (en) | 2004-10-14 |
Family
ID=32029407
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2003/031072 WO2004028434A2 (en) | 2002-09-27 | 2003-09-26 | Nocturnal muscle enhancing composition and method |
Country Status (3)
Country | Link |
---|---|
US (2) | US7037522B2 (en) |
AU (1) | AU2003299088A1 (en) |
WO (1) | WO2004028434A2 (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1774858A1 (en) * | 2005-10-13 | 2007-04-18 | Valpharma International S.P.A. | Nutritional compositions based on amino acids |
EP1774973A1 (en) * | 2005-10-12 | 2007-04-18 | Nutricia N.V. | Leucine rich composition |
WO2011004132A1 (en) | 2009-07-10 | 2011-01-13 | Sanofi-Aventis | Novel hsp90-inhibiting indole derivatives, compositions containing said derivatives, and use thereof |
WO2011027081A2 (en) | 2009-09-03 | 2011-03-10 | Sanofi-Aventis | Novel derivatives of 5,6,7,8-tetrahydroindolizine inhibiting hsp90, compositions containing same, and use thereof |
US9642390B2 (en) | 2008-07-02 | 2017-05-09 | N.V. Nutricia | Nutritional composition for improving muscle function and daily activity |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE502006008291D1 (en) * | 2005-08-23 | 2010-12-23 | Herberger Armand | PROTEIN COMPOSITION FOR TREATING A PHYSIOLOGICALLY CONDITIONAL, CLINICALLY INVALID PROTEIN SUPPLY |
US20080124286A1 (en) * | 2006-11-28 | 2008-05-29 | Lisson Jerold B | Algae supplement and treatment method |
US20080124318A1 (en) * | 2006-11-28 | 2008-05-29 | Jerold Lisson | Algae supplement and treatment method |
US20080250971A1 (en) * | 2007-04-16 | 2008-10-16 | Sivapackia Ganapathiappan | Polymer-encapsulated pigment with passivation layer |
US20130004599A1 (en) * | 2011-06-30 | 2013-01-03 | Masada Health & Beauty Corporation | Formulation for transdermal delivery to promote sleep |
US9198889B2 (en) | 2012-09-19 | 2015-12-01 | Quality IP Holdings, LLC | Methods for treating post-traumatic stress disorder |
US10300101B2 (en) | 2012-09-19 | 2019-05-28 | Quality IP Holdings, LLC | Methods and compositions for enhancing or maintaining fertility |
US8747921B2 (en) | 2012-09-19 | 2014-06-10 | Quality Ip Holdings, Inc. | Methods for improving health in humans |
US8747922B2 (en) | 2012-09-19 | 2014-06-10 | Quality Ip Holdings, Inc. | Methods and compositions for increasing sex steroids and growth hormones |
US8551542B1 (en) * | 2012-09-20 | 2013-10-08 | Basic Research L.L.C. | Methods and compositions for increasing growth hormones |
US8734864B2 (en) * | 2012-09-20 | 2014-05-27 | Quality Ip Holdings, Inc. | Methods for increasing human growth hormone levels |
US8747923B2 (en) | 2012-09-20 | 2014-06-10 | Quality Ip Holdings, Inc. | Methods for improving health in canines |
US8715752B2 (en) | 2012-09-20 | 2014-05-06 | Quality Ip Holdings, Inc. | Compositions for increasing human growth hormone levels |
US10292957B2 (en) | 2012-09-20 | 2019-05-21 | Quality IP Holdings, LLC | Compositions and methods for treating fibromyalgia |
US9066953B2 (en) | 2012-09-20 | 2015-06-30 | Quality IP Holdings, LLC | Methods for increasing endurance and fat metabolism in humans |
GB201312245D0 (en) * | 2013-07-08 | 2013-08-21 | Gorman Eddie O | An extrusion process |
JOP20190146A1 (en) | 2016-12-19 | 2019-06-18 | Axcella Health Inc | Amino acid compositions and methods for the treatment of liver diseases |
US10894072B2 (en) | 2017-02-13 | 2021-01-19 | IP Quality Holdings, LLC | Compositions and methods for treating fibromyalgia |
CN111295187A (en) | 2017-08-14 | 2020-06-16 | 胺细拉健康公司 | Amino acid composition for treating liver diseases |
CN112839643A (en) | 2018-06-20 | 2021-05-25 | 胺细拉健康公司 | Compositions and methods for treating fat infiltration in muscle |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4356166A (en) * | 1978-12-08 | 1982-10-26 | University Of Utah | Time-release chemical delivery system |
US5534496A (en) * | 1992-07-07 | 1996-07-09 | University Of Southern California | Methods and compositions to enhance epithelial drug transport |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5637319A (en) * | 1995-03-01 | 1997-06-10 | Takada; Kanji | Controlled-release preparations |
PT923315E (en) * | 1996-08-30 | 2004-04-30 | Nestle Sa | NUTRITIONAL FORMULA FOR PATIENTS WITH FENILCETONURIA |
US5902797A (en) * | 1997-11-10 | 1999-05-11 | Beth Israel Deaconess Medical Center | Nutritional supplement for use in the treatment of attention deficit |
US6329539B1 (en) * | 1998-05-25 | 2001-12-11 | Taisho Pharmaceutical Co., Ltd. | Prostagladin derivatives |
BR0007360A (en) * | 1999-12-23 | 2001-08-14 | Johnson & Johnson | Controlled release composition |
US6475530B1 (en) * | 2000-05-31 | 2002-11-05 | Eric H. Kuhrts | Methods and compositions for producing weight loss |
US7790670B2 (en) * | 2002-03-01 | 2010-09-07 | Glanbia Nutritionals (Ireland) Ltd. | Compositions and methods for treatment of body weight conditions |
US20030215506A1 (en) * | 2002-05-17 | 2003-11-20 | Kuhrts Eric H | Methods and compositions for enhancement of creatine transport |
-
2002
- 2002-09-27 US US10/256,997 patent/US7037522B2/en not_active Expired - Fee Related
-
2003
- 2003-09-26 WO PCT/US2003/031072 patent/WO2004028434A2/en not_active Application Discontinuation
- 2003-09-26 AU AU2003299088A patent/AU2003299088A1/en not_active Abandoned
-
2006
- 2006-03-14 US US11/374,872 patent/US7300665B2/en not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4356166A (en) * | 1978-12-08 | 1982-10-26 | University Of Utah | Time-release chemical delivery system |
US5534496A (en) * | 1992-07-07 | 1996-07-09 | University Of Southern California | Methods and compositions to enhance epithelial drug transport |
Non-Patent Citations (1)
Title |
---|
KRAMER W. ET AL.: 'Intestinal absorption of peptides by coupling to bile acids' JOURNAL OF BIOLOGICAL CHEMISTRY vol. 269, no. 14, 08 April 1994, pages 10621 - 10627, XP002975776 * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1774973A1 (en) * | 2005-10-12 | 2007-04-18 | Nutricia N.V. | Leucine rich composition |
EP1774858A1 (en) * | 2005-10-13 | 2007-04-18 | Valpharma International S.P.A. | Nutritional compositions based on amino acids |
US9642390B2 (en) | 2008-07-02 | 2017-05-09 | N.V. Nutricia | Nutritional composition for improving muscle function and daily activity |
US9950013B2 (en) | 2008-07-02 | 2018-04-24 | N. V. Nutricia | Nutritional composition for improving muscle function and daily activity |
WO2011004132A1 (en) | 2009-07-10 | 2011-01-13 | Sanofi-Aventis | Novel hsp90-inhibiting indole derivatives, compositions containing said derivatives, and use thereof |
WO2011027081A2 (en) | 2009-09-03 | 2011-03-10 | Sanofi-Aventis | Novel derivatives of 5,6,7,8-tetrahydroindolizine inhibiting hsp90, compositions containing same, and use thereof |
Also Published As
Publication number | Publication date |
---|---|
WO2004028434A3 (en) | 2004-10-14 |
US20060153898A1 (en) | 2006-07-13 |
AU2003299088A1 (en) | 2004-04-19 |
US7300665B2 (en) | 2007-11-27 |
US7037522B2 (en) | 2006-05-02 |
US20040063608A1 (en) | 2004-04-01 |
AU2003299088A8 (en) | 2004-04-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7300665B2 (en) | Nocturnal muscle enhancing composition and method | |
CN101061860B (en) | Leucine-rich nutritional compositions | |
US7445807B2 (en) | Agglomerated granular protein-rich nutritional supplement | |
US8168241B2 (en) | Performance-enhancing dietary supplement | |
US7288570B2 (en) | Stimulation of in vivo production of proteins | |
US10842839B2 (en) | Natural formulation for treating hangover | |
US20040120983A1 (en) | Nutritional supplement | |
US20080317886A1 (en) | Compositions for Preventing and Reducing Delayed Onset Muscle Soreness | |
KR20020090214A (en) | αLIPOIC ACID BASED FOOD SUPPLEMENT FOR INCREASING LEAN MUSCLE MASS AND STRENGTH | |
WO1999055326A1 (en) | Method of treatment of glutathione deficient mammals | |
CA2228049C (en) | Two-phase preparation | |
WO2004089110A2 (en) | Hydration beverage and method of delivering nutrients | |
GB2268871A (en) | Composition for use as a food or food supplement | |
AU2002310212B2 (en) | Method and composition for enhancing sexual desire | |
RU2335927C2 (en) | Nutrient compositions enriched with leucine | |
JPH01269456A (en) | Food for sport | |
US7390513B2 (en) | Food supplement formulation | |
RU2323599C1 (en) | Biologically active food additive and its production method | |
TWI692313B (en) | Use of sports supplement composition | |
US20050143343A1 (en) | Nutritional supplement for enhancing the production and effect of natural human growth hormone | |
EP2042170B1 (en) | Creatine composition and use | |
JP2000516937A (en) | Vitamin preparations that reduce oxygen consumption during exercise | |
UA143083U (en) | FUNCTIONAL COMPOSITION FOR ENRICHMENT OF FOOD PRODUCTS OF SPECIAL DIETARY CONSUMPTION (FOR ATHLETES) | |
CA2488463C (en) | Creatine composition and use | |
JP2007507441A (en) | Immune system activation composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |